Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects with Early Alzheimer's Disease

Trial Profile

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects with Early Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elenbecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MissionAD2
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 02 Dec 2019 According to an Eisai media release, data from MissionAD global phase 3 studies will be presented at at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference (4th-7th Dec 2019) in San Diego.
    • 14 Oct 2019 This trial has been discontinued in Finland, according to European Clinical Trials Database record.
    • 13 Sep 2019 According to an Eisai Co Ltd media release, Eisai And Biogen have decided to discontinue MISSION AD1 and MISSION AD2 trials as per the recommendation of the Data Safety Monitoring Board (DSMB), due to unfavorable risk-benefit ratio.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top